Literature DB >> 10459910

QT lengthening and life-threatening arrhythmias associated with fexofenadine.

Y M Pinto, I C van Gelder, M Heeringa, H J Crijns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10459910     DOI： 10.1016/s0140-6736(99)01009-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  25 in total

1.  Intranasal corticosteroids in allergic rhinitis. Paper did not include all data on adverse effects.

Authors:  D Paddon
Journal:  BMJ       Date:  1999-05-15

Review 2.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Torsades de Pointes.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-08

4.  Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries.

Authors:  Fabrizio De Ponti; Elisabetta Poluzzi; Alberto Vaccheri; Ulf Bergman; Lars Bjerrum; John Ferguson; Kerry J Frenz; Peter McManus; Ingrid Schubert; Gisbert Selke; Georgia Terzis-Vaslamatzis; Nicola Montanaro
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 5.  Causality assessment of adverse effects: when is re-challenge ethically acceptable?

Authors:  A L Po; M J Kendall
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 6.  Thorough QT Studies: Questions and Quandaries.

Authors:  Marek Malik; Christine E Garnett; Joanne Zhang
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

7.  Facts, fancies and follies of drug-induced QT/QTc interval shortening.

Authors:  Marek Malik
Journal:  Br J Pharmacol       Date:  2010-01       Impact factor: 8.739

8.  The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia.

Authors:  Constanze R Scherer; Christian Lerche; Niels Decher; Adrienne T Dennis; Patrick Maier; Eckhard Ficker; Andreas E Busch; Bernd Wollnik; Klaus Steinmeyer
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

9.  Intentional rechallenge: does the benefit outweigh the risk?

Authors:  Vid Stanulović; Mauro Venegoni; Brian Edwards
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

Review 10.  Ebastine: an update of its use in allergic disorders.

Authors:  M Hurst; C M Spencer
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.